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Some preclinical and pharmacokinetic studies suggested the variable safety and the potential efficacy of an antifungal prophy-
laxis with a single high dose of liposomal amphotericin B (L-AmB) in high-risk patients. An open-label, prospective study was
conducted with 48 adults receiving induction chemotherapy for acute myeloid leukemia (AML). Patients received a single infu-
sion of 15 mg/kg of body weight L-AmB and, eventually, a second dose after 15 days of persistent neutropenia. The primary ob-
jective was tolerability and safety. Efficacy was also evaluated as a secondary endpoint. A pharmacokinetic study was performed
with 34 patients in order to evaluate any association of plasma L-AmB levels with toxicity and efficacy. Overall, only 6 patients
(12.5%) reported Common Toxicity Criteria (CTC) grade 3 hypokalemia, which was corrected with potassium supplementation
in all cases, and no patient developed clinically relevant nephrotoxicity. Mild infusion-related adverse events occurred after 6 of
53 (11.3%) total infusions, with permanent drug discontinuation in only one case. Proven invasive fungal disease (IFD) was di-
agnosed in 4 (8.3%) patients. The mean AmB plasma levels at 6 h, 24 h, and 7 days after L-AmB administration were 160, 49.5,
and 1mg/liter, respectively. The plasma AmB levels were higher than the mean values of the overall population in 3 patients who
developed CTC grade 3 hypokalemia and did not significantly differ from the mean values of the overall population in 3 patients
who developed IFD. Our experience demonstrates the feasibility and safety of a single 15-mg/kg L-AmB dose as antifungal pro-
phylaxis in AML patients undergoing induction chemotherapy.
Invasive fungal diseases (IFDs), in particular invasive aspergillo-sis (IA), are a leading cause of morbidity and mortality in pa-
tients with acute myeloid leukemia (AML) (1–4). Primary anti-
fungal prophylaxis has been considered an appealing strategy,
because the diagnosis of IFD is often difficult to obtain in time to
implement an early and effective therapeutic intervention. How-
ever, despite the availability of various broad-spectrum antifungal
drugs suitable for prophylaxis use, only oral posaconazole has
proven to be effective in this setting and is actually recommended
as the drug of choice for the prevention of IFDs in AML patients
undergoing induction chemotherapy (5–12). However, a major
problem with the use of oral posaconazole in patients treated with
intensive chemotherapy is represented by the unpredictable gas-
trointestinal absorption, which may require monitoring of tria-
zole plasma levels; the possible difficulty in taking oral medica-
tions; and some drug-drug interactions, which may limit the use
of this drug, as well as of the other triazoles, in patients receiving
certain antileukemic treatments (13–17). Therefore, other classes
of antifungals may be considered prophylaxis in some particular
settings.
The liposomal form of AmB (L-AmB) has been investigated in
order to evaluate the feasibility of its use in primary prophylaxis of
IFDs in patients with hematological malignancies receiving che-
motherapy or stem cell transplant (SCT) (18–28). Some preclini-
cal and pharmacokinetic studies suggested the relevance of a high-
dose regimen of L-AmB (7.5 to 15 mg/kg of body weight)
administered as long-interval infusions (once weekly) or as a sin-
gle administration in the prophylaxis of IFDs (25–28). All these
experiences demonstrated variable safety and clinical attractive-
ness of long intervals or single, high-dose, prophylactic schedules
of L-AmB in certain high-risk populations, but this has not been
adequately investigated for AML patients.
The aim of this pilot study was to evaluate the feasibility and
tolerability of prophylactic administration of a single very high
dose (15 mg/kg) of L-AmB in adult patients newly diagnosed with
AML and undergoing induction chemotherapy.
MATERIALS AND METHODS
Study design. This study was a prospective, pilot, phase II, single-center
trial. This study aimed to assess the feasibility and tolerability of a single
very high dose of L-AmB (15 mg/kg/infusion) in 48 adult patients newly
diagnosed with AML undergoing first-remission induction chemother-
apy. Efficacy was also evaluated as a secondary endpoint. A pharmacoki-
netic study was also performed with 34 patients in order to evaluate any
association of plasma L-AmB levels with toxicity and efficacy. Patients
were enrolled between January 2004 and January 2011. The study was
performed according to institutional guidelines and was approved by the
local review board in compliance with good clinical practices and the
Declaration of Helsinki. Written informed consent was obtained from
each patient before any study procedure was performed.
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Patient population. Patients were eligible for the study if they were
18 years old, underwent first-remission induction chemotherapy, and
had expected neutropenia of500 neutrophils/ml for at least 2 weeks.
Patients should not have had any evidence of invasive mycosis at the
onset of leukemia before the start of chemotherapy; therefore, all patients
by protocol underwent a chest computed tomography (CT) scan as a
baseline screening in order to exclude any pulmonary infection. Patients
should not have received any other concomitant antifungal prophylaxis.
Also, patients were not eligible for enrollment into the study if the serum
creatinine level was1.5 times the upper limit of our laboratory value and
if the potassium serum level was 3.0 mEq/liter. Patients with severe
cardiovascular disease, severe disease other than hematological disease,
and pregnancy were not eligible. Patients were hospitalized in single-bed
rooms with HEPA filtration and positive pressure. Antibacterial prophy-
laxis consisted of oral ciprofloxacin (500 mg/twice a day [b.i.d.]).
Chemotherapy procedures. Patients underwent induction chemo-
therapy protocols according to age (60 years or60 years) and type of
AML (most of the patients were enrolled in the EORTC-GIMEMA stud-
ies), as detailed in Table 1 (29–32).
Study drug administration. L-AmB (Ambisome; Gilead Sciences,
Paris, France) was reconstituted, according to the manufacturer’s instruc-
tions, to give a 2-mg/ml solution. Drug dilutions for injection were pre-
pared as needed with 5% dextrose. All patients received a single intrave-
nous L-AmB administration at a dose of 15 mg/kg as a 6-h infusion within
24 h after the stop of chemotherapy. A second 15-mg/kg dose was even-
tually administered to patients with persistent profound neutropenia
(100 neutrophils/l) after 15 days from the first L-AmB dose. Premed-
ication was not administered per protocol for infusion-related reactions
prior to the study drug infusion.
Monitoring of safety and tolerability. In order to monitor the safety
and tolerability of L-AmB infusions, patients were closely observed for
infusion-related side effects during the administration of study drug and
during the following 12 h. Serial vital signs during and after infusion as
well as clinical signs and symptoms of toxicity were recorded. Pulse and
blood pressure were monitored immediately before infusion, during in-
fusion if necessary, and at the end of infusion. Signs, symptoms, and
reported side effects associated with drug infusion or occurring at any
time during the study period were documented and assessed for a rela-
tionship to the study drug. Routine laboratory examinations (blood
counts and determination of serum creatinine, uric acid, aspartate ami-
notransferase, alanine aminotransferase, alkaline phosphatase, total bili-
rubin, sodium, potassium, phosphate, calcium, magnesium, and glucose
levels) for assessment of safety were performed daily for the first 15 days
and then at least every other day until patient discharge. Safety and toler-
ability were assessed according to the incidence of grade 3 to 4 adverse
events (AEs) based on the Common Toxicity Criteria (CTC) classifica-
tion, reported as definitely, possibly, or probably related to the study drug.
In particular, CTC grade 3 and grade 4 hypokalemia was defined as po-
tassium serum levels of3 mmol/liter and2.5 mmol/liter, respectively,
and CTC grade 3 and grade 4 acute kidney injury was defined as creatinine
levels3 baseline serum levels and dialysis indication, respectively. Any
adverse event with onset during or within 1 h of completion of the study
drug infusion was recorded as an infusion-related reaction.
Assessment of efficacy. Efficacy assessment was based on a clinically
driven diagnostic workup. In the event of fever or other clinical signs
potentially related to an underlying infection, patients underwent physi-
cal examination; serial blood cultures; cultures from other sites if indi-
cated; and CT scan of the chest, paranasal sinuses, and abdomen. Bron-
choalveolar lavage and biopsy of suspicious lesions/sites with microscopic
evaluation and cultures were done at the discretion of the investigator.
Since January 2007, serum Aspergillus galactomannan (Platelia Aspergil-
lus) and Candida mannan (Platelia Candida) tests were also used in the
diagnostic workup. Generally, patients who died underwent autopsy. Di-
agnosis of IFD was done according to the European Organization for
Research and Treatment of Cancer-Mycoses Study Group (EORTC-
MSG) criteria published in 2002 (33).
Pharmacokinetic study. Overall, 34 patients were evaluable for AmB
pharmacokinetics, all after the first L-AmB infusion. Blood samples were
taken immediately before L-AmB administration (T0), at the end of the
6-h infusion (T6), and at 24 h (T24) and 7 days from the start of L-AmB
administration. Amphotericin B concentrations were determined by
high-performance liquid chromatography (HPLC) of plasma sample ex-
tracts.
Chromatography was performed with a Perkin-Elmer series 200 high-
performance liquid chromatograph connected to a Perkin-Elmer series
200 fluorometer and autoinjector from Perkin-Elmer Instruments, Nor-
walk, CT. Data collection and processing were carried out by using a
Totalchrome WS HPLC IPM chromatography data system (Perkin-Elmer
Instruments, Norwalk, CT). The mobile phase consisted of acetonitrile–
0.7 M EDTA (36:64, vol/vol) at a flow rate of 1.0 ml/min. Separation was
performed by reverse-phase chromatography on a Bondclone C18 column
(3.9 by 150 mm, 10 m; Phenomenex) with a C18 guard cartridge packed
with the same material. Detection was done by measurement of the ab-
sorbance at 405 nm.
An aliquot of plasma samples (500 l) was extracted with acetonitrile
(0.5 ml) containing 50l of the internal standardN-acetylamphotericin B
at a 5-mg/liter final concentration. The mixture was vortex mixed briefly
and centrifuged at 1,200 g for 10 min twice.
The layer was transferred into clean tubes and was evaporated to dry-
ness at 37°C. The residue was reconstituted in 500l of the mobile phase,
and the components were mixed for 20 s; this was followed by centrifu-
gation. The aqueous layer was transferred into injection vials, and 50-l
aliquots were injected into the HPLC system.
Standards were prepared by adding the diluted amphotericin B solu-
tion, and the internal standard, to appropriate volumes of plasma to give
a total volume of 0.5 ml and concentrations of 0.15, 0.3, 0.6, 1.25, 2.5, 5,
and 10 g/ml. The standard curves for amphotericin B were constructed
by weighted linear regression of the peak area-versus-concentration ratio
and were linear in the concentration ranges. The lowest concentration of
the prepared standards was used as the limit of quantification for each
assay. If the concentration of a sample was above the range of the standard
curve, a dilution of the sample was made in appropriate medium, and the
sample was reassayed. The final concentration was calculated by multiply-
ing the concentration of the diluted sample obtained by the assay by the
dilution factor. When the concentration of a sample was below the detec-
TABLE 1 Patient demographics and clinical characteristics
Characteristic Value
No. (%) of male patients 29 (61.7)
Median age (yr) (range) 55 (32–78)
No. (%) of patients with type of leukemia
Nonpromyelocitic AML 42 (87.5)
Acute promyelocitic leukemia 6 (12.5)
No. of patients in chemotherapy protocola
AML-12 14
AML-17 5
AML-19 2
AIDA 6
3 7 11
FLAG 9
No. (%) of patients with de novo AML 40 (83.3)
No. (%) of patients with secondary AMLb 8 (16.7)
a See references 29–32.
b AML occurring after a myelodysplastic phase or other hematologic or solid tumor.
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tion limit, it was not used in the analyses. To investigate the accuracy and
precision of each assay, quality control samples (e.g., standards prepared
identically to, but independently from, those of the standard curve) were
assayed with each standard curve in each assay run. The assay was linear
over a concentration range of 0.15 to 10g/ml in plasma. Validation data
for accuracy and precision were a coefficient of variation (CV) of between
2.7 and 9.5%, and intraday accuracy was in the range of 99.9 to 105.5%.
Analysis. The primary endpoints were tolerability and safety, defined
by infusion-related side effects and the incidence of AEs occurring within
4 weeks from the administration of prophylactic treatment. The second-
ary endpoints were prophylaxis efficacy (incidence of proven and proba-
ble IFDs within 1 month from L-AmB administration), use of empirical
antifungal therapy (in patients with persistent fever of unknown origin
during postinduction chemotherapy), use of preemptive antifungal ther-
apy (in patients with clinical and/or microbiological findings suspected to
be related to an underlying IFD but not fulfilling the EORTC-MSG crite-
ria for proven-probable IFD), and survival at 3 months. Death was attrib-
uted to IFD in patients who failed to respond to therapy (i.e., who had
stable disease or disease progression) and in patients with a partial re-
sponse to therapy who died as the result of an acute event involving any of
the sites of infection or of an unknown cause.
Descriptive statistics included absolute and relative frequencies for
categorical data and median, mean, and range for numerical measure-
ments.
RESULTS
Demographic and clinical characteristics of patients are summa-
rized in Table 1. All 48 patients received at least one prophylactic
dose (median, 1,000 mg; standard deviation [SD], 193 mg;
range, 550 to 1,300 mg), whereas 5 patients with prolonged severe
neutropenia received a second prophylactic dose (median, 900
mg; SD,185 mg; range, 900 to 1,300 mg).
Primary endpoints. Overall, 18 of the 48 (37.5%) patients ex-
perienced at least one AE (all CTC grade) after the first or the
second L-AmB infusion, and only 6 of them (12.5%) reported a
CTC grade 3 AE probably related to L-AmB administration.
The main AEs observed after 53 L-AmB infusions are detailed
in Table 2.
CTC grade 3 hypokalemia was documented in 6 cases (11.3%)
3, 5, 5, 6, and 10 days from the first L-AmB infusion and 5 days
from the second infusion, respectively. In one of these cases, CTC
grade 3 hypokalemia was also associated with CTC grade 2 acute
kidney injury. In all cases, hypokalemia was corrected with intra-
venous potassium supplementation. An increased infusion dura-
tion for better tolerance was required in 4 cases (7.5%), and in
only 1 case (1.9%) was the infusion permanently discontinued due
to the patient’s refusal to continue the treatment after the devel-
opment of abdominal pain. For this patient, no alternative anti-
fungal prophylaxis was administered.
Secondary endpoints. Data on proven-probable IFDs docu-
mented within 1 month from L-AmB administration, use of em-
pirical or preemptive antifungal therapy, and 3-month survival
rate are detailed in Table 3. Proven IFD was diagnosed in 4 (8.3%)
patients (2 cases of pulmonary aspergillosis, 1 case of pulmonary
mucormycosis, and 1 case of disseminated Geotrichum capitatum
infection). The first infectious clinical signs for the 4 proven IFDs
were observed at 8, 8, 10, and 11 days from L-AmB administra-
tion, respectively. Empirical and preemptive (for a possible pul-
monary IFD) antifungal therapy was administered to one patient
each. Thirteen deaths (27.1%) occurred within 3 months from the
first L-AmB administration; four deaths were attributed to a
proven IFD.
Pharmacokinetic analysis. Plasma samples at T0, T6, and T24
were available for all 34 patients evaluated for pharmacokinetics,
whereas plasma samples at day 7 were available for only 27 pa-
tients. The pharmacokinetic data are detailed in Table 3. The
mean (SD) AmB plasma levels at T6, T24, and day 7 were 160
(72), 49.5 (19.1), and 1 (1.1) mg/liter, respectively.
Out of 34 patients considered for the pharmacokinetic evalu-
ation, 3 developed CTC grade 3 hypokalemia. The plasma AmB
levels were higher than the mean values of the overall population
for all 3 patients at T6 (300, 230, and 180 mg/liter, respectively)
and at T24 (72, 84, and 78 mg/liter, respectively) and for 1 of them
at day 7 (0.3, 2.6, and 0.4 mg/liter, respectively).
The plasma levels of 3 patients who developed IFD despite
L-AmB prophylaxis did not significantly differ from the mean
values of the overall population.
DISCUSSION
The aim of the present study was to investigate the safety and
feasibility of a single very high dose of L-AmB administered as
TABLE 2 CTC AEs observed after 53 L-AmB infusions in 48 patients
CTC
No. (%) of L-AmB infusions
All CTC grade
AEs
CTC grade 3–4
AEs
L-AmB infusions with at least one AE 19 (35.8) 6 (11.3)a
Infusion-related AEs
Abdominal pain 1(1.9) 0
Lumbar pain 1 (1.9) 0
Pruritus 1 (1.9) 0
Skin rash 2 (3.8)c 0
Chills 2 (3.8)c 0
AEs subsequent to L-AmB infusion
Serum creatinine level increase 4 (7.5) 0
Hypokalemia 14 (26.4) 6 (11.3)a
Infusion-related AEs that caused increase
of infusion duration for better
tolerance
4 (7.5) 0
Infusion-related AEs that caused
permanent infusion discontinuation
1 (2.1)b 0
a All CTC grade 3, with 5 AEs after the first L-AmB infusion and 1 AE after the second
one.
b The patient developed abdominal pain and refused to continue the infusion.
c One patient developed both chills and skin rash after the same infusion.
TABLE 3 Pharmacokinetic analysis
Time of blood sample
collection after L-AmB
infusion
Mean AmB plasma level (mg/liter) (SD)
Total patients
(n 34 for
T6 and T24;
n 27 for
day 7)
Patients who
developed
CTC grade 3
hypokalemia
(n 3)
Patients who
developed
invasive
fungal disease
(n 3)
T6 160 (72) 237 (60.3) 164 (19.7)
T24 49.5 (19.1) 78 (6.0) 49.3 (9.0)
7 days from the start of
infusion
1 (1.1) 1.1 (1.3) 0.9 (0.2)
Annino et al.
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antifungal prophylaxis in AML patients undergoing first-remis-
sion induction chemotherapy. Overall, 48 patients were enrolled
in the study, and this is the largest experience of high-dose L-AmB
prophylaxis in this category of high-risk patients reported in the
literature so far. The biological rationale of this schedule of L-
AmB prophylaxis derives from previous studies in neutropenic
animals suggesting that the administration of a single dose of L-
AmB of up to 20 mg/kg of body weight can prevent infections due
to yeasts or molds (34, 35). Higher L-AmB doses produce in-
creased intravascular concentrations, which may facilitate its pen-
etration into tissues with sustained concentrations sufficiently
high to provide prophylactic efficacy against fungi for several
weeks posttreatment (36). In a study on pharmacokinetics and
safety of extended-interval dosing of prophylactic L-AmB in stem
cell transplant recipients, different schedules of L-AmB adminis-
tration were evaluated (28). A single L-AmB dose of 15 mg/kg
produced mean plasma concentrations of 0.491 mg/liter for at
least 7 days. Furthermore, measurement of buccal mucosal tissue
concentrations showed that high levels of the drug, well in excess
of the MICs reported in the literature for susceptible strains of
Candida and Aspergillus spp., continued to be detected 2 weeks
after a single 15-mg/kg dose of L-AmB. Of interest, the buccal
mucosal concentrations increased 33% from day 7 to day 15.
These pharmacokinetic data suggest that a single very high dose of
L-AmB administered at the onset of the period of infectious risk
may be considered antifungal prophylaxis with a presumable effi-
cacy of at least 2 weeks.
The main result of our experience is represented by the favor-
able safety profile of the antifungal prophylaxis schedule. Al-
though CTC grade 3 hypokalemia was observed after 11.3% of
infusions, the electrolyte abnormality was still easily and quickly
corrected with potassium supplementation and without clinically
significant consequences. With regard to renal toxicity, only a
mild and self-limiting increase of the serum creatinine level was
observed. The continuous hydration with careful electrolyte mon-
itoring usually performed at our institution for leukemic patients
undergoing intensive chemotherapy may have contributed to the
low toxicity of the treatment. Again, infusion-related reactions
occurred after 6 infusions; the infusion duration was prolonged to
achieve better tolerance in only 4 cases, and the infusion was
stopped by decision of the patient in only 1 case. The low inci-
dence of infusion-related side effects in our series may have been
related to the longer infusion time (6 h) that we used than in
previous studies reported in the literature (2 to 4 h) (25–28). Con-
sidering the data of the pharmacokinetic study performed with 34
patients, we observed that for the 3 patients who developed CTC
grade 3 hypokalemia, the levels at T6 and at T24 were higher than
the mean values of the overall population. Presumably, the higher
the peak level of AmB, the higher the distal tubular epithelial tox-
icity, with increased urinary potassium wasting and hypokalemia.
This effect was observed within a few days after L-AmB infusion
and rapidly disappeared.
Several studies reported in the last years, most of which were
published since the initiation of the present pilot study, have
shown a variable tolerance of L-AmB given as antifungal prophy-
laxis in neutropenic and SCT patients (Table 4). Various admin-
istration schedules in different hematologic populations have
been used. When daily to weekly low or standard doses (from 1 to
3 mg/kg) of L-AmB were used, the toxicity profile was generally
favorable (18–24). On the contrary, the use of high L-AmB doses
(7.5 to 15 mg/kg) administered at weekly intervals or as a single
administration was in some cases associated with severe adverse
events, leading to the treatment discontinuation (25–28). In par-
ticular, a significant toxicity of high doses of L-AmB was observed
in adult SCT patients (26–28). In the PROPHYSOME study,
where 10-mg/kg L-AmB doses were planned to be administered
weekly for 8 weeks in allogeneic SCT patients, 6 of the first 8 SCT
patients enrolled in the study developed various CTC grade 3 to 4
AEs (dyspnea, thoracic pain, abdominal pain, tubulointerstitial
nephritis, anuria, and anaphylactic shock), leading the indepen-
dent data review committee to stop the inclusion of SCT subjects
(27).
The toxicity observed in SCT patients was not confirmed in
nontransplant neutropenic patient populations. In agreement
with our experience, the PROPHYSOME study showed a good
toxicity profile of high-dose L-AmB antifungal prophylaxis (10
mg/kg/week for 4 weeks) in acute leukemia patients undergoing
intensive chemotherapy (27).
Our study was not primarily designed to measure prophylactic
efficacy of a single 15-mg/kg L-AmB dose, and the 8.3% incidence
of IFDs that we observed, although similar to or lower than that
reported for real-life experiences of posaconazole prophylaxis in
AML patients (6–8), does not allow any interpretation. However,
in agreement with previous pharmacokinetic studies, the median
day 7 plasma L-AmB concentration in our patients was within the
range of MICs for susceptible strains of Candida (0.25 to 1 mg/
liter) and at the lower limits for Aspergillus (0.5 to 2 mg/liter). In
any case, it was difficult to find a correlation between AmB plasma
levels and efficacy of the prophylaxis regimen considering the
highly variable interpatient plasma concentration-time data; fur-
thermore, the plasma levels of the 3 patients who developed IFD
and were evaluated for pharmacokinetics did not significantly dif-
fer from the mean values of the overall population.
In conclusion, our prospective experience demonstrates the
feasibility and safety of a single very high L-AmB dose as antifun-
gal prophylaxis in AML patients undergoing induction chemo-
therapy. The challenging aspect of this particular schedule of
mold-active prophylaxis is the single intravenous administration,
which may be repeated in the event of prolonged neutropenia. It
may be an alternative to oral triazoles (itraconazole, posaconazole,
and voriconazole), which have the limits of gastrointestinal ab-
sorption, metabolic variability, and drug-drug interactions, or to
other mold-active intravenous drugs (echinocandins, voricona-
zole, and itraconazole), which require daily administration during
the entire at-risk period. The pharmacokinetic studies of patients
receiving a single very high L-AmB dose demonstrated the
achievement of prolonged serum and tissue therapeutic levels of
the drug, and published uncontrolled clinical series, including the
present one, suggest a promising clinical efficacy of this prophy-
lactic schedule. Prospective, controlled clinical trials are needed to
verify the potential efficacy of a single very high L-AmB dose as an
alternative prophylaxis choice for acute leukemia patients under-
going intensive chemotherapy.
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